Citations

Mayo Clinic

Showing 10 of 108602 citations.

Recent Advances in Upper Extremity Arthroplasty
Schuind, Frédéric , An, Kalil

Recent Advances in Upper Extremity Arthroplasty | October 4, 2017 | Volume: No volume available | Issue: No issue available | Pages: 1-359

10.1142/9789814531078 Get It

Quantitative Imaging System for Cancer Diagnosis and Treatment Planning: An Interdisciplinary Approach
Gaw, Nathan , Xu, Yanzhe , Wang, Lujia , Fu, Yinlin, Silva, Alvin, Zwart, Christine M. , DeLeon, Thomas, Wu, Teresa , Li, Jing , Borad, Mitesh J. , Patel, Bhavika

The Operations Research Revolution | October 4, 2017 | Volume: No volume available | Issue: No issue available | Pages: 152-175

10.1287/educ.2017.0173 Get It

Narrow-Complex Tachycardia in a Woman With a 20-Year History of Supraventricular Tachycardia
Naksuk, Niyada , Kancharla, Krishna , Madhavan, Malini

JAMA Internal Medicine | October 4, 2017 | Volume: 177 | Issue: 11 | Pages: 1676

10.1001/jamainternmed.2017.4785 | PMID 28975216 Get It

Contemporary Primary Prevention Aspirin Use by Cardiovascular Disease Risk: Impact of US Preventive Services Task Force Recommendations, 2007—2015: A Serial, Cross‐sectional Study
Hof, Jeremy Van’t , Duval, Sue , Walts, Adrienne, Kopecky, Stephen L. , Luepker, Russell V. , Hirsch, Alan T.

Journal of the American Heart Association | October 4, 2017 | Volume: 6 | Issue: 10 | Pages: No page available

10.1161/jaha.117.006328 | PMID 28974502 Get It

Background No previous study has evaluated the impact of past US Preventive Services Task Force statements on primary prevention ( PP ) aspirin use in a primary care setting. The aim of this study was to evaluate temporal changes in PP aspirin use in a primary care population, stratifying patients by their 10‐year global cardiovascular disease risk, in response to the 2009 statement. Methods and Results This study estimated biannual aspirin use prevalence using electronic health record data from primary care clinics within the Fairview Health System (Minnesota) from 2007 to 2015. A total of 94 270 patient encounters had complete data to estimate a 10‐year cardiovascular disease risk score using the 2013 American College of Cardiology/American Heart Association global risk estimator. Patients were stratified into low‐ (<10%), intermediate‐ (10–20%), and high‐ (≥20%) risk groups. Over the 9‐year period, PP aspirin use averaged 43%. When stratified by low, intermediate and high risk, average PP aspirin use was 41%, 63%, and 73%, respectively. Average PP aspirin use decreased after the publication of the 2009 US Preventive Services Task Force recommendation statement: from 45% to 40% in the low‐risk group; from 66% to 62% in the intermediate‐risk group; and from 76% to 73% in the high‐risk group, before and after the guideline. Conclusions Publication of the 2009 US Preventive Services Task Force recommendation was not associated with an increase in aspirin use. High risk PP patients utilized aspirin at high rates. Patients at intermediate risk were less intensively treated, and patients at low risk used aspirin at relatively high rates. These data may inform future aspirin guideline dissemination.
Longitudinal Heart Failure Medication Use and Adherence Following Left Ventricular Assist Device Implantation in Privately Insured Patients
Tan, Nicholas Y. , Sangaralingham, Lindsey R. , Schilz, Stephanie R., Dunlay, Shannon M.

Journal of the American Heart Association | October 4, 2017 | Volume: 6 | Issue: 10 | Pages: No page available

10.1161/jaha.117.005776 | PMID 28974501 Get It

Background There are few data describing the longitudinal use of and adherence to heart failure medications following left ventricular assist device (LVAD) implantation. Methods and Results Using a large US commercial insurance database, patients who received an LVAD ( International Classification of Diseases, 9th Revision, Clinical Modification code 37.66) and survived to hospital discharge without heart transplantation between January 1, 2006, and March 31, 2015, were identified. Heart failure medication use from 3 months before 1‐year post‐ LVAD was examined using linked pharmacy claims. Differences in the proportion of patients taking heart failure medications post LVAD compared with pre LVAD were examined using McNemar test. Predictors of post‐ LVAD medication use and poor medication adherence (proportion of days covered <0.8) were identified via logistic regression. Among 362 patients (mean age, 57.4 years; 75.1% men), compared with pre LVAD , the proportion of patients taking anticoagulants and antiarrhythmics following LVAD increased; mineralocorticoid receptor antagonists, thiazide diuretics, and digoxin decreased; and β‐blockers, angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, and loop diuretics did not change. Pre‐ LVAD medication use was associated with post‐ LVAD use across all medication classes. The proportion of patients with poor medication adherence was 28.8%, 39.0%, and 36.0% for β‐blockers, angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, and anticoagulants, respectively. Many patients with poor adherence completely discontinued use of the medication. Conclusions Neurohormonal antagonist use after LVAD was inconsistent, perhaps reflecting uncertainty of therapeutic benefit in this population. Medication adherence post‐ LVAD was poor in many patients. Further work is needed to delineate the reasons for nonadherence after LVAD .
Contractile Smooth Muscle and Active Stress Generation in Porcine Common Carotids
Zhou, Boran , Prim, David A., Romito, Eva, McNamara, Liam P., Spinale, Francis G. , Shazly, Tarek , Eberth, John F. , Romito, Eva A.

Journal of Biomechanical Engineering | October 3, 2017 | Volume: 140 | Issue: 1 | Pages: No page available

10.1115/1.4037949 | PMID 28975258 Get It

The mechanical response of intact blood vessels to applied loads can be delineated into passive and active components using an isometric decomposition approach. Whereas the passive response is due predominantly to the extracellular matrix (ECM) proteins and amorphous ground substance, the active response depends on the presence of smooth muscle cells (SMCs) and the contractile machinery activated within those cells. To better understand determinants of active stress generation within the vascular wall, we subjected porcine common carotid arteries (CCAs) to biaxial inflation–extension testing under maximally contracted or passive SMC conditions and semiquantitatively measured two known markers of the contractile SMC phenotype: smoothelin and smooth muscle-myosin heavy chain (SM-MHC). Using isometric decomposition and established constitutive models, an intuitive but novel correlation between the magnitude of active stress generation and the relative abundance of smoothelin and SM-MHC emerged. Our results reiterate the importance of stretch-dependent active stress generation to the total mechanical response. Overall these findings can be used to decouple the mechanical contribution of SMCs from the ECM and is therefore a powerful tool in the analysis of disease states and potential therapies where both constituent are altered.
Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Lohavanichbutr, Pawadee, Arnold, Susanne M. , Davies, Michael P.A. , Field, John K. , Haura, Eric B. , Hung, Rayjean J., Kohno, Takashi , Landi, Maria Teresa , Liu, Geoffrey , Marcus, Michael W. , O’Kane, Grainne M. , Schabath, Matthew B. , Slone, Stacey , Tardón, Adonina , Yoshida, Kazushi, Zong, Xuchen, Goodman, Gary E. , Chen, Chu , Hung, Rayjean J. , Hung, Rayjean J , Liu, Geoffrey , Field, John K , Tardón, Adonina , Davies, Michael P A , Schabath, Matthew B , Sakoda, Lori C. , Amos, Christopher I. , Christiani, David C. , Liu, Yi , Shiraishi, Kouya , Yang, Ping , Zhang, Ruyang , Weiss, Noel S , Arnold, Susanne M , O'Kane, Grainne M.

Clinical Cancer Research | October 3, 2017 | Volume: 23 | Issue: 24 | Pages: 7550-7557

10.1158/1078-0432.ccr-17-1401 | PMID 28974547 Get It

Abstract Purpose: DNA topoisomerase inhibitors are commonly used for treating small-cell lung cancer (SCLC). Tyrosyl-DNA phosphodiesterase (TDP1) repairs DNA damage caused by this class of drugs and may therefore influence treatment outcome. In this study, we investigated whether common TDP1 single-nucleotide polymorphisms (SNP) are associated with overall survival among SCLC patients. Experimental Design: Two TDP1 SNPs (rs942190 and rs2401863) were analyzed in 890 patients from 10 studies in the International Lung Cancer Consortium (ILCCO). The Kaplan–Meier method and Cox regression analyses were used to evaluate genotype associations with overall mortality at 36 months postdiagnosis, adjusting for age, sex, race, and tumor stage. Results: Patients homozygous for the minor allele (GG) of rs942190 had poorer survival compared with those carrying AA alleles, with a HR of 1.36 [95% confidence interval (CI): 1.08–1.72, P = 0.01), but no association with survival was observed for patients carrying the AG genotype (HR = 1.04, 95% CI, 0.84–1.29, P = 0.72). For rs2401863, patients homozygous for the minor allele (CC) tended to have better survival than patients carrying AA alleles (HR = 0.79; 95% CI, 0.61–1.02, P = 0.07). Results from the Genotype Tissue Expression (GTEx) Project, the Encyclopedia of DNA Elements (ENCODE), and the ePOSSUM web application support the potential function of rs942190. Conclusions: We found the rs942190 GG genotype to be associated with relatively poor survival among SCLC patients. Further investigation is needed to confirm the result and to determine whether this genotype may be a predictive marker for treatment efficacy of DNA topoisomerase inhibitors. Clin Cancer Res; 23(24); 7550–7. ©2017 AACR.
Vascularized Bone Grafts in Orthopaedic Surgery
Shin, Emily H. , Shin, Alexander Y.

JBJS Reviews | October 3, 2017 | Volume: 5 | Issue: 10 | Pages: e1-e1

10.2106/jbjs.rvw.16.00125 | PMID 28976444 Get It

* Preclinical animal studies have demonstrated that vascularized bone grafts increase blood flow, maintain patent pedicles, provide immediate structural integrity, hypertrophy in response to mechanical stress, and deliver proper environments for healing in challenging situations. * The absolute indications for vascularized bone graft as borne out by high-quality studies have yet to be defined. Currently, the literature suggests varying success rates for difficult reconstructive problems requiring additional biological and structural properties offered only by vascularized bone-grafting. * Orthopaedic reconstructive challenges can be met with a variety of options, including pedicled and free vascularized bone grafts.
Characteristics of Novel Therapeutics and Postmarket Safety Events—Reply
Downing, Nicholas S., Shah, Nilay D. , Ross, Joseph S. , Ross, Joseph S

JAMA | October 3, 2017 | Volume: 318 | Issue: 11 | Pages: 1067

10.1001/jama.2017.11517 | PMID 28975302 Get It

Carotid Endarterectomy and Carotid Artery Stenting in the US Medicare Population, 1999-2014
Lichtman, Judith H. , Jones, Michael R. , Leifheit, Erica C , Sheffet, Alice J., Howard, George , Lal, Brajesh K. , Howard, Virginia J. , Wang, Yun , Curtis, Jeptha P. , Brott, Thomas G. , Howard, Virginia J , Howard, George

JAMA | October 3, 2017 | Volume: 318 | Issue: 11 | Pages: 1035

10.1001/jama.2017.12882 | PMID 28975306 Get It